Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility

BMC Gastroenterology

Margarida D Amaral³  José D Ribeiro²  Antônio F Ribeiro²  Karl Kunzelmann¹  Rita B de Carvalho⁴  Luciana R Meirelles⁴  Maria A Ribeiro²  Silvia R Cardoso⁵  Adriana M Vinagre⁷  Marisa Sousa⁶  Maria F Servidoni⁸ 

[1] Institut für Physiologie - Universität Regensburg, Universitat Strasse 31, D-93053, Regensburg, Germany;CIPED - Research Center in Pediatrics - State University of Campinas (Unicamp) - Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-872, Brazil;University of Lisboa - Faculty of Sciences, BioFIG - Centre for Biodiversity, Functional and Integrative Genomics, Campo Grande, 1749-016, Lisbon, Portugal;Pathological Anatomy Department, University Hospital of Campinas (Unicamp) - Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-872, Brazil;Endoscopy Unit – University Hospital of Campinas, Campinas, Brazil;Department of Genetics, National Institute of Health – Av. Padre Cruz, 1649-016, Lisbon, Portugal;Faculty of Medical Sciences - State University of Campinas (Unicamp) - Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-872, Brazil;Post-graduate Course, Pediatrics Department, State University of Campinas (Unicamp) - Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-872, Brazil

关键词: Rectal biopsy;    Outcome measures clinical trial;    Forceps;    Patient comfort;    Quality control;   

Others  :  857953
DOI  :  10.1186/1471-230X-13-91

 received in 2012-06-30, accepted in 2013-05-16,  发布年份 2013

【 摘 要 】

Background

Measurements of CFTR function in rectal biopsies ex vivo have been used for diagnosis and prognosis of Cystic Fibrosis (CF) disease. Here, we aimed to evaluate this procedure regarding: i) viability of the rectal specimens obtained by biopsy forceps for ex vivo bioelectrical and biochemical laboratory analyses; and ii) overall assessment (comfort, invasiveness, pain, sedation requirement, etc.) of the rectal forceps biopsy procedure from the patients perspective to assess its feasibility as an outcome measure in clinical trials.

Methods

We compared three bowel preparation solutions (NaCl 0.9%, glycerol 12%, mannitol), and two biopsy forceps (standard and jumbo) in 580 rectal specimens from 132 individuals (CF and non-CF). Assessment of the overall rectal biopsy procedure (obtained by biopsy forceps) by patients was carried out by telephone surveys to 75 individuals who underwent the sigmoidoscopy procedure.

Results

Integrity and friability of the tissue specimens correlate with their transepithelial resistance (r = −0.438 and −0.305, respectively) and are influenced by the bowel preparation solution and biopsy forceps used, being NaCl and jumbo forceps the most compatible methods with the electrophysiological analysis. The great majority of the individuals (76%) did not report major discomfort due to the short procedure time (max 15 min) and considered it relatively painless (79%). Importantly, most (88%) accept repeating it at least for one more time and 53% for more than 4 times.

Conclusions

Obtaining rectal biopsies with a flexible endoscope and jumbo forceps after bowel preparation with NaCl solution is a safe procedure that can be adopted for both adults and children of any age, yielding viable specimens for CFTR bioelectrical/biochemical analyses. The procedure is well tolerated by patients, demonstrating its feasibility as an outcome measure in clinical trials.

【 授权许可】

   
2013 Servidoni et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM, McCann JD, Klinger KW, Smith AE, Welsh MJ: Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990, 347(6291):358-363.
• [2]Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science 1992, 256(5058):774-779.
• [3]Rosenstein BJ, Cutting GR: The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998, 132(4):589-595.
• [4]Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Vicky A, Massie J, Parad RB: Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatrics 2008, 153(2):S4-S14.
• [5]Wallis C: Atypical cystic fibrosis—diagnostic and management dilemmas. J Royal Soc Med 2003, 96(Suppl 43):2-10.
• [6]Paranjape SM, Zeitlin PL: Atypical cystic fibrosis and CFTR-related diseases. Clin Rev Allerg Immunol 2008, 35(3):116-23.
• [7]Boyle MP: Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003, 9(6):498-503.
• [8]De B, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M: Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006, 61(7):627-635.
• [9]Taylor CJ, Hardcastle J, Southern KW: Physiological Measurements Confirming the Diagnosis of Cystic Fibrosis : the Sweat Test and Measurements of Transepithelial Potential Difference. Paediatr Respir Rev 2009, 10:220-226.
• [10]Com G: Cystic fibrosis newborn screening. J Arkansas Med Soc 2010, 106(9):210-2.
• [11]Sermet-Gaudelus I, Mayell SJ, Southern KW: Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J Cyst Fibros 2010, 9(5):323-329.
• [12]Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AINAI, Barreto C, Ramalho A, Amaral MD, Kunzelmann K, Mall M: CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004, 127(4):1085-1095.
• [13]Mall M, Hirtz S, Gonska T, Kunzelmann K: Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros 2004, 3(Suppl 2):165-169.
• [14]Sousa M, Servidoni M, Vinagre A, Ramalho A, Bonadia L, Felício V, Ribeiro M, Uliyakina I, Marson F, Kmit A, Cardoso S, Ribeiro J, Bertuzzo C, Sousa L, Kunzelmann K, Ribeiro A, Amaral MD: Measurements of CFTR-mediated Cl- Secretion in Human Rectal Biopsies Constitute a Robust Biomarker for Cystic Fibrosis Diagnosis and Prognosis. PLoS One 2012, 7(10):e47708.
• [15]de Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tummler B, Sinaasappel M: Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 2004, 3(Suppl 2):159-163.
• [16]Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tümmler B, Gallati S, Ballmann M: Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010, 65(7):594-9.
• [17]Veeze H, Sinaasappel M, Bijman J, Bouquet J, de Jonge H: Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 1991, 101(2):398-403.
• [18]Veeze HJ, Halley DJ, Bijman J, Jongste JC, de Jonge HR, Sinaasappel M: Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994, 93:461-466.
• [19]Mall M, Greger R, Seydewitz H, Kuehr J, Brandis M, Kunzelmann K: Detection of defective cholinergic Cl- secretion in human rectal biopsies for the diagnosis of Cystic Fibrosis. J Clin Invest 1998, 102:15-21.
• [20]Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH, Amaral MD, Mall MA: The K Channel Opener 1-EBIO Potentiates Residual Function of Mutant CFTR in Rectal Biopsies from Cystic Fibrosis Patients. PLoS One 2011, 6(8):e24445.
• [21]Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW: Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Eng J Med 2010, 363(21):1991-2003.
• [22]Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, Deboeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2011, 67(1):12-8.
• [23]Shah S: VX-770, a CFTR potentiator, may have a potential clinical benefit in a subgroup of people with cystic fibrosis. Thorax 2011, 66(11):984.
• [24]McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, Adler A, Cho D, Boscardin WJ, Soto-Torres L, Anton PA: Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 2007, 46:417-425.
• [25]Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Rabe L, Mccormick T, Gabelnick H, Carballo-die A, Mcgowan I: First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy. PLoS One 2011, 6(9):e23243.
• [26]Mall M, Bleich M, Kuehr J, Brandis M, Greger R, Kunzelmann K: CFTR-mediated inhibition of epithelial Na + conductance in human colon is defective in cystic fibrosis. Am J Physiol 1999, 277(3 Pt 1):G709-16.
• [27]Mendes F, Farinha CM, Roxo-Rosa M, Fanen P, Edelman A, Dormer R, McPherson M, Davidson H, Puchelle E, De JH, Heda GD, Gentzsch M, Lukacs G, Penque D, Amaral MD: Antibodies for CFTR studies. J Cyst Fibros 2004, 3(Suppl 2):69-72.
• [28]Mall M, Kreda SM, Mengos A, Jensen TJ, Hirtz S, Seydewitz HH, Yankaskas J, Kunzelmann K, Riordan JR, Boucher RC: The DF508 Mutation Results in Loss of CFTR Function and Mature Protein in Native Human Colon. Gastroenterology 2004, 126:32-41.
• [29]Ousingsawat J, Mirza M, Tian Y, Roussa E, Schreiber R, Cook DI, Kunzelmann K: Rotavirus toxin NSP4 induces diarrhea by activation of TMEM16A and inhibition of Na + absorption. Pflugers Arch 2011, 461:579-89.
• [30]Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, Kunzelmann K: Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Oncogene 2010, 29:1553-60.
• [31]Kunzelmann K: Ion channels and cancer. J Membr Biol 2005, 205:159-73.
• [32]Stanke F, Ballmann M, Bronsveld I, Dörk T, Gallati S, Laabs U, Derichs N, Ritzka M, Posselt H, Harms H, Griese M, Blau H, Mastella G, Bijman J, Veeze H, Tümmler B: Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. J Med Genet 2008, 45(1):47-54.
• [33]van Barneveld A, Stanke F, Tamm S, Siebert B, Brandes G, Derichs N, Ballmann M, Junge S, Tümmler B, Barneveld AV: Functional analysis of F508del CFTR in native human colon. Biochim Biophys Acta 2010, 1802(11):1062-9.
• [34]Cohen-Cymberknoh M, Yaakov Y, Shoseyov D, Shteyer E, Schachar E, Rivlin J, Bentur L, Picard E, Aviram M, Israeli E, Kerem E, Wilschanski M: Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. Pediatr Pulmonol 2012. May 2: [Epub ahead of print]
• [35]Hug M, Derichs N, Bronsveld I, Clancy JP: Measurement of ion transport function in rectal biopsies. In Cystic fibrosis-diagnosis and protocols. Volume I: approaches to study and correct CFTR defects, Volume 741. Edited by Amaral M, Kunzelmann K. New York: Methods Mol Biol; Springer Science; 2011:87-107.
• [36]Bronsveld I, Mekus F, Bijman J, Ballmann M, Greipel J, Hundrieser J, Halley DJ, Laabs U, Busche R, De Jonge HR, Tümmler B, Veeze HJ: Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology 2000, 119:32-40.
• [37]van Barneveld A, Stanke F, Tamm S, Siebert B, Brandes G, Derichs N, Ballmann M, Junge S, Tümmler B: Functional analysis of F508del CFTR in native human colon. Biochim Biophys Acta 1802, 2010:1062-9.
• [38]Hirsch BZ, Angelides AG, Goode SP, Garb JL: Rectal Biopsies Obtained With Jumbo Biopsy Forceps in the Evaluation of Hirschsprung Disease. J Pediatr Gastroenterol Nutr 2011, 52:429-432.
• [39]Elmunzer B, Higgins P, Kwon Y, Golembeski C, Greenson JK, Korsnes SJ, Elta GH: Jumbo forceps are superior to standard large-capacity forceps in obtaining diagnostically adequate inflammatory bowel disease surveillance biopsy specimens. Gastrointest Endosc 2008, 68:273-8.